516 related articles for article (PubMed ID: 15837752)
1. N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers.
Hiramatsu K; Takahashi K; Yamaguchi T; Matsumoto H; Miyamoto H; Tanaka S; Tanaka C; Tamamori Y; Imajo M; Kawaguchi M; Toi M; Mori T; Kawakita M
Clin Cancer Res; 2005 Apr; 11(8):2986-90. PubMed ID: 15837752
[TBL] [Abstract][Full Text] [Related]
2. [Clinical usefulness of urinary diacetylpolyamines as novel tumor markers].
Kawakita M; Hiramatsu K; Sugimoto M; Takahashi K; Toi M
Rinsho Byori; 2004 Apr; 52(4):321-7. PubMed ID: 15164599
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the utility of N1,N12-diacetylspermine and N1,N8-diacetylspermidine in urine as tumor markers for breast and colorectal cancers.
Umemori Y; Ohe Y; Kuribayashi K; Tsuji N; Nishidate T; Kameshima H; Hirata K; Watanabe N
Clin Chim Acta; 2010 Dec; 411(23-24):1894-9. PubMed ID: 20655890
[TBL] [Abstract][Full Text] [Related]
4. [The significance of urine di-acetyl spermine level as a cancer marker for colorectal cancer].
Takahashi K; Hiramatsu K; Kawakita M; Mori T; Yamaguchi T; Matsumoto H; Miyamoto H; Tamamori Y
Rinsho Byori; 2004 Apr; 52(4):332-5. PubMed ID: 15164601
[TBL] [Abstract][Full Text] [Related]
5. [Urine diacetylspermine as a novel tumor marker for pancreatobiliary carcinomas].
Yamaguchi K; Nagano M; Torada N; Hamasaki N; Kawakita M; Tanaka M
Rinsho Byori; 2004 Apr; 52(4):336-9. PubMed ID: 15164602
[TBL] [Abstract][Full Text] [Related]
6. Determination of N¹,N¹²-diacetylspermine in urine: a novel tumor marker.
Kawakita M; Hiramatsu K; Yanagiya M; Doi Y; Kosaka M
Methods Mol Biol; 2011; 720():367-78. PubMed ID: 21318886
[TBL] [Abstract][Full Text] [Related]
7. [Urinary diacetylspermine: its analysis and performance as a novel tumor marker].
Kawakita M; Hiramatsu K; Takahashi K; Yamada R; Kawaguchi M; Shinoura N; Tanaka T; Kariyone K; Tamamori Y; Sasaki Y; Mori T
Rinsho Byori; 2005 Feb; 53(2):123-9. PubMed ID: 15796045
[TBL] [Abstract][Full Text] [Related]
8. Identification of Cystatin SN as a novel tumor marker for colorectal cancer.
Yoneda K; Iida H; Endo H; Hosono K; Akiyama T; Takahashi H; Inamori M; Abe Y; Yoneda M; Fujita K; Kato S; Nozaki Y; Ichikawa Y; Uozaki H; Fukayama M; Shimamura T; Kodama T; Aburatani H; Miyazawa C; Ishii K; Hosomi N; Sagara M; Takahashi M; Ike H; Saito H; Kusakabe A; Nakajima A
Int J Oncol; 2009 Jul; 35(1):33-40. PubMed ID: 19513549
[TBL] [Abstract][Full Text] [Related]
9. Diacetylated derivatives of spermine and spermidine as novel promising tumor markers.
Kawakita M; Hiramatsu K
J Biochem; 2006 Mar; 139(3):315-22. PubMed ID: 16567395
[TBL] [Abstract][Full Text] [Related]
10. Urine diacetylspermine as a novel tumour maker for pancreatobiliary carcinomas.
Yamaguchi K; Nakamura M; Shirahane K; Konomi H; Torata N; Hamasaki N; Kawakita M; Tanaka M
Dig Liver Dis; 2005 Mar; 37(3):190-4. PubMed ID: 15888284
[TBL] [Abstract][Full Text] [Related]
11. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
Zhao XW; Jiang B; Han CZ; Jing JX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
[TBL] [Abstract][Full Text] [Related]
12. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer.
Ogawa Y; Ishikawa T; Ikeda K; Nakata B; Sawada T; Ogisawa K; Kato Y; Hirakawa K
Clin Cancer Res; 2000 Oct; 6(10):4069-72. PubMed ID: 11051258
[TBL] [Abstract][Full Text] [Related]
14. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
[TBL] [Abstract][Full Text] [Related]
15. [Usefulness of preoperative assay CEA and CA 19-9 in colorectal cancer patients].
Grotowski M; Maruszyński M; Piechota W
Pol Merkur Lekarski; 2001 Dec; 11(66):476-9. PubMed ID: 11899841
[TBL] [Abstract][Full Text] [Related]
16. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
[TBL] [Abstract][Full Text] [Related]
17. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
18. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
Guadagni F; Ferroni P; Carlini S; Mariotti S; Spila A; Aloe S; D'Alessandro R; Carone MD; Cicchetti A; Ricciotti A; Venturo I; Perri P; Di Filippo F; Cognetti F; Botti C; Roselli M
Clin Cancer Res; 2001 Aug; 7(8):2357-62. PubMed ID: 11489813
[TBL] [Abstract][Full Text] [Related]
19. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
20. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
